article thumbnail

Reducing Drug Spend with IV Robotic Services

Omnicell

Director, Central Pharmacy Product Marketing, Omnicell IV automation technology combined with robust expert services is a game-changer for reducing drug spend while enhancing patient safety. Register today at Omnicell Illuminate 2021. Dennis Wright Sr. The number of improperly prepared IVs is staggering.

article thumbnail

NASP 2022 Reveals a Pharmacy Landscape Shifting to Specialty

Omnicell

Kristen Dowd Director, Pharmacy Management Services, Omnicell If the 2022 NASP (National Association of Specialty Pharmacy) Annual Meeting and Expo is any indication, we are approaching a time when specialty pharmacy simply becomes pharmacy – when complex, high-touch biologics become nearly as ubiquitous as their broad-spectrum counterparts.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Advocates for Safe IV Preparation Practices Share Their Inspiration Podcast

Omnicell

His was a leading voice in persuading the FDA to require bar codes on all immediate drug containers. We’ll be sharing our insights into this crucial topic and sharing our experiences in one of the highest risk areas of pharmacy. He is the tenth recipient of the Institute for Safe Medication Practices’ Lifetime Achievement Award.

article thumbnail

What Exactly is Herd Immunity?

Omnicell

Ken Perez Vice President of Healthcare Policy and Government Affairs at Omnicell All About Herd Immunity You’ve probably heard the term “herd immunity” debated and discussed in the news. Food and Drug Administration (FDA) granted Emergency Use Authorization to Johnson & Johnson’s vaccine. 27, the U.S.

article thumbnail

Healthcare Implications of Biden’s Latest Executive Order

Omnicell

It directs the Food and Drug Administration (FDA) to work with states and tribes to safely import prescription drugs from Canada, and it also encourages the Federal Trade Commission (FTC) to ban “pay for delay” agreements in which brand-name drug manufacturers pay generic manufacturers to stay out of the market.